
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings is expected to see a decrease in annual revenue of $7.1M due to a restructured contract with their largest biomedical services customer. Despite this, pro forma revenue is expected to grow 6-8% and adjusted EBITDA margin is expected to improve thanks to planned reductions in expenses and increased efficiency benefits. The company's core oncology business is performing well, and they are investing in new growth drivers such as wound care and pain management. While regulatory setbacks and competition could potentially impede growth, the company's strong operating cash flow, repurchasing of stock, and strong liquidity give a positive outlook for its stock.
Bears say
InfuSystems Holdings is facing ongoing competitive pressures from larger players such as McKesson and Option Care Health. Additionally, the company's significant reliance on third-party payers for revenue raises vulnerability to potential changes in coverage policies and reimbursement rates, which could negatively impact margins. Furthermore, any delays in growth drivers such as Wound Care and Pain Management becoming material contributors could impede achieving the target price of $15.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares